Silk Road Medical Inc

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Silk Road Medical Inc reports robust Q4 performance and eyes global expansion

Silk Road Medical Inc's Q4 2022 performance reflects strong revenue growth and operational efficiency, supported by a focus on market expansion and cost management.
While facing challenges in cost control and operational metrics, the company's strategic initiatives and revenue guidance for 2023 signal growth potential.
Opportunities lie in leveraging the cash balance for growth, expanding TCAR utilization, and addressing analyst concerns to drive future success.

Silk Road Medical reports robust Q1 earnings and eyes international expansion

Silk Road Medical's Q1 2023 earnings call highlighted strong revenue growth, innovative product launches, and strategic international expansion plans.
While the company faces challenges in scaling operations and managing costs, it remains well-positioned with a solid financial foundation and a focus on driving sustainable growth.
With a clear focus on optimizing revenue per procedure and expanding geographically, Silk Road Medical is poised to capitalize on opportunities for market growth and product adoption.

Silk Road Medical Inc posts strong Q2 earnings, eyes global expansion

Silk Road Medical Inc delivered robust Q2 2023 results, showcasing revenue growth, product advancements, and strategic progress. While facing competition and regulatory challenges, the company is well-positioned to capitalize on international markets and drive further growth through operational efficiency.

Silk Road Medical posts strong Q3 results, eyes growth opportunities

Silk Road Medical's Q3 2023 earnings call highlighted robust financial performance, leadership changes, strategic initiatives, and market opportunities. The company faces challenges in sales force management and margin optimization but is well-positioned to capitalize on growth prospects.

Silk Road Medical reports robust 2023 earnings, eyes international expansion

Silk Road Medical's strong financial performance in 2023, driven by revenue growth and strategic initiatives, sets the stage for continued success.
While facing challenges such as sales force turnover and market dynamics, the company's focus on innovation and international expansion presents opportunities for growth.
Maintaining a stable pricing strategy, deepening physician adoption, and leveraging new product advancements are key to Silk Road's sustainable growth strategy.
Navigating competition in carotid treatments and maximizing the adoption curve for TCAR procedures are critical areas for Silk Road's future success.

Silk Road Medical reports robust Q1 earnings and eyes international growth

Silk Road Medical's Q1 2024 performance reflects revenue growth, improved EBITDA, and strong financial stability despite operational challenges.
The company's strengths lie in its leadership in carotid treatment, growth opportunities in international markets, and innovative product development.
Challenges include profitability concerns, margin pressure, and the need for efficient cost management amid rising expenses.
Opportunities for Silk Road Medical include market expansion, revenue growth, and continued innovation to solidify its position as a leader in carotid treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

SUNNYVALE, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2020.

Silk Road Medical Reports Third Quarter 2020 Financial Results

SUNNYVALE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming Stifel 2020 Virtual Healthcare Conference.

Silk Road Medical to Present at the Stifel 2020 Virtual Healthcare Conference

Silk Road Medical (SILK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Silk Road Medical (SILK) Q3 Earnings Expected to Decline

SUNNYVALE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silk Road Medical to Report Third Quarter 2020 Financial Results on November 10, 2020

SUNNYVALE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that medical device industry veteran Rick Anderson has joined its board of directors.

Silk Road Medical Names Rick Anderson to Board of Directors

SUNNYVALE, Calif., Sept.  21, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it is strengthening its leadership team with two appointments. William Whealon, Ph.D. has joined the company as Executive Vice President of Research and Development, effective immediately. Silk Road Medical has also named Lucas Buchanan, the company’s current Chief Financial Officer, to also serve as its Chief Operating Officer, effective October 1, 2020.

Silk Road Medical Strengthens Leadership Team

SUNNYVALE, Calif., Sept.  21, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that positive results from the ongoing TransCarotid  Artery Revascularization (TCAR) Surveillance Project comparing TCAR and carotid endarterectomy (CEA) have been published in Annals of Surgery  1 .

Compelling Outcomes with TCAR vs. CEA in Patients with Carotid Artery Stenosis Published in the Annals of Surgery

Alarm.com

Avalara Inc

Etsy

National Vision Hlds

Five9

Freshpet

iRhythm Technologies

Lumentum Holdings

Mimecast

Natera

Palomar

Q2 Hld

SPS Commerce

For this report, we analyzed the portfolios of the 13 small-cap growth investment managers with the best 10-year performance records.

Positions In The Portfolios Of The Best-Performing Small-Cap Growth Funds

SUNNYVALE, Calif., Sept.  04, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming Morgan Stanley 2020 Healthcare Conference.

Silk Road Medical to Present at the Morgan Stanley 2020 Healthcare Conference

SUNNYVALE, Calif., Aug.  19, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that ROADSTER 2 study results have been published in the latest edition of the American Heart Association’s journal, Stroke. The article, “Early Outcomes in the ROADSTER 2 Study of TransCarotid Artery Revascularization (TCAR) in Patients with Significant Carotid Artery Disease” demonstrates compelling patient outcomes with low stroke and combined stroke and death rates when utilizing TCAR.

ROADSTER 2 Data Publication in Stroke Demonstrates Compelling Patient Outcomes and Strong Safety Profile with TCAR

Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q2 2020 Results - Earnings Call Transcript

SUNNYVALE, Calif., Aug.  05, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2020.

Silk Road Medical Reports Second Quarter 2020 Financial Results

Earnings Preview: Silk Road Medical (SILK) Q2 Earnings Expected to Decline

SUNNYVALE, Calif., July  23, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the second quarter 2020 after market close on Wednesday, August 5, 2020. Company management will host a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.

Silk Road Medical to Report Second Quarter 2020 Financial Results on August 5, 2020

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

While most attention in health care has been going to large pharma companies, the charts suggest opportunities in niche subsectors.

Health Care Services and Equipment Stocks Poised for Gains

SUNNYVALE, Calif., July  09, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that Andrew Davis has been promoted to Chief Commercial Officer.

Silk Road Medical Promotes Andrew Davis to Newly Created Position of Chief Commercial Officer

New Guidelines Consistent with Silk Road Medical Certification Process

Society for Vascular Surgery (SVS) Issues Guidance on Competence Recommendations for TCAR

SUNNYVALE, Calif., May  20, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced that in connection with its previously announced public offering of 6,808,154 shares of its common stock, the underwriters fully exercised and closed on their option to purchase up to an additional 1,021,223 shares of common stock from certain selling securityholders at the public offering price of $39.00 per share, less the underwriting discounts and commissions. Silk Road Medical did not receive proceeds from the sale of its common stock by the selling securityholders.

Silk Road Medical Announces Full Exercise and Closing of Over-Allotment Option

SUNNYVALE, Calif., May  08, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the closing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share. 1,923,076 shares in the offering were offered for sale by Silk Road Medical, and 4,885,078 million shares were offered for sale by certain selling securityholders. Gross proceeds from the offering to Silk Road Medical were approximately $75 million.  The selling stockholders granted the underwriters a 30-day option to purchase up to an additional 1,021,223 shares of common stock at the public offering price, less the underwriting discounts and commissions. Silk Road Medical did not receive proceeds from the sale of its common stock by the selling securityholders.

Silk Road Medical Announces Closing of Follow-on Public Offering

Investors responded negatively to the medical device company's pricing of a public stock offering.

Why Silk Road Medical Stock Is Sinking Today

SUNNYVALE, Calif. , May  05, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the pricing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share, before deducting underwriting discounts and commissions. 1,923,076 shares in the offering are being offered for sale by Silk Road Medical, and 4,885,078 shares are being offered for sale by certain selling securityholders. In addition, the selling securityholders have granted the underwriters a 30-day option to purchase up to an additional 1,021,223 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering to Silk Road are expected to be approximately $75 million. Silk Road Medical will not receive proceeds from the sale of its common stock by selling securityholders. The offering is expected to close on May 8, 2020, subject to the satisfaction of customary closing conditions.

Silk Road Medical Announces Pricing of Upsized Public Offering

Silk Road Medical, Inc. (SILK) CEO Erica Rogers on Q1 2020 Results - Earnings Call Transcript

SUNNYVALE, Calif., April  06, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today provided a corporate update in response to the COVID-19 pandemic.

Silk Road Medical Provides COVID-19 Pandemic Update

Silk Road Medical Seeks Continued Growth Amid High Operating Losses

SUNNYVALE, Calif., March  05, 2020  (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, announced today that effective as of market open on March 6, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "SILK".

News for Silk Road Medical Inc Stock (SILK)